Metastatic colorectal cancer- third line therapy and beyond

被引：1

作者：

Foo, Tiffany ^{[1
,2
]}

Roy, Amitesh ^{[3
,4
]}

Karapetis, Christos ^{[3
,4
]}

Townsend, Amanda ^{[1
,2
]}

Price, Timothy ^{[1
,2
]}

机构：

[1] Queen Elizabeth Hosp, Dept Med Oncol, Woodville South, SA 5011, Australia

[2] Univ Adelaide, Woodville South, SA 5011, Australia

[3] FCIC, Dept Med Oncol, Bedford Pk, SA, Australia

[4] Flinders Univ S Australia, Bedford Pk, SA, Australia

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 05期

关键词：

Metastatic colorectal cancer; immunotherapy; targeted therapy; biomarkers; refractory disease; OPEN-LABEL; DOUBLE-BLIND; TAS-102; MONOTHERAPY; 1ST-LINE TREATMENT; REPAIR-DEFICIENT; ASIAN PATIENTS; SINGLE-ARM; PLACEBO; PLUS; REGORAFENIB;

D O I：

10.1080/14737140.2024.2334784

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IntroductionThe outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.MethodIn this narrative review, we provide a comprehensive summary of data from key clinical trials and discuss how to integrate these agents into the current treatment landscape of metastatic colorectal cancer.Expert OpinionIn the era of precision medicine, molecular testing plays an increasingly important role in the management of mCRC. Efforts need to be made to target treatment based on molecular test results.

引用

页码：219 / 227

页数：9

共 66 条

[1] A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis [J].

Abrahao, Ana B. K. ;

Ko, Yoo-Joung ;

Berry, Scott ;

Chan, Kelvin K. W. .

CLINICAL COLORECTAL CANCER, 2018, 17 (02) :113-120

[2] EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer [J].

Amodio, Vito ;

Yaeger, Rona ;

Arcella, Pamela ;

Cancelliere, Carlotta ;

Lamba, Simona ;

Lorenzato, Annalisa ;

Arena, Sabrina ;

Montone, Monica ;

Mussolin, Benedetta ;

Bian, Yu ;

Whaley, Adele ;

Pinnelli, Marika ;

Murciano-Goroff, Yonina R. ;

Vakiani, Efsevia ;

Valeri, Nicola ;

Liao, Wei-Li ;

Bhalkikar, Anuja ;

Thyparambil, Sheeno ;

Zhao, Hui-Yong ;

de Stanchina, Elisa ;

Marsoni, Silvia ;

Siena, Salvatore ;

Bertotti, Andrea ;

Trusolino, Livio ;

Li, Bob T. ;

Rosen, Neal ;

Di Nicolantonio, Federica ;

Bardelli, Alberto ;

Misale, Sandra .

CANCER DISCOVERY, 2020, 10 (08) :1129-1139

[3] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 [J].

Andre, T. ;

Lonardi, S. ;

Wong, K. Y. M. ;

Lenz, H. -J ;

Gelsomino, F. ;

Aglietta, M. ;

Van Cutsem, E. ;

McDermott, R. ;

Hill, A. ;

Sawyer, M. B. ;

Hendlisz, A. ;

Neyns, B. ;

Abdullaev, S. ;

Memaj, A. ;

Lei, M. ;

Dixon, M. ;

Kopetz, S. ;

Overman, M. J. ;

Morse, M. A. .

ANNALS OF ONCOLOGY, 2022, 33 (10) :1052-1060

[4] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[5]

[Anonymous], FDA APPR ENTR NTRK S

[6]

[Anonymous], 2023, FDA grants accelerated approval for Alzheimers disease treatment.

[7]

[Anonymous], FDA APPR LAR SOL TUM

[8] DNA mismatch repair in cancer [J].

Baretti, Marina ;

Le, Dung T. .

PHARMACOLOGY & THERAPEUTICS, 2018, 189 :45-62

[9] A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer [J].

Bertotti, Andrea ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Sassi, Francesco ;

Torti, Davide ;

Isella, Claudio ;

Cora, Davide ;

Di Nicolantonio, Federica ;

Buscarino, Michela ;

Petti, Consalvo ;

Ribero, Dario ;

Russolillo, Nadia ;

Muratore, Andrea ;

Massucco, Paolo ;

Pisacane, Alberto ;

Molinaro, Luca ;

Valtorta, Emanuele ;

Sartore-Bianchi, Andrea ;

Risio, Mauro ;

Capussotti, Lorenzo ;

Gambacorta, Marcello ;

Siena, Salvatore ;

Medico, Enzo ;

Sapino, Anna ;

Marsoni, Silvia ;

Comoglio, Paolo M. ;

Bardelli, Alberto ;

Trusolino, Livio .

CANCER DISCOVERY, 2011, 1 (06) :508-523

[10] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumors [J].

Cao, Junning ;

Zhang, Jian ;

Peng, Wei ;

Chen, Zhiyu ;

Fan, Songhua ;

Su, Weiguo ;

Li, Ke ;

Li, Jin .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) :259-269

← 1 2 3 4 5 6 7 →